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Abstract
Circulating tumor cells (CTCs) are isolated tumor cells
disseminated from the site of disease in metastatic
and/or primary cancers, including breast cancer, that
can be identified and measured in the peripheral
blood of patients. As recent technical advances have
rendered it easier to reproducibly and repeatedly
sample this population of cells with a high degree of
accuracy, these cells represent an attractive surrogate
marker of the site of disease.
Currently, CTCs are being integrated into clinical trial
design as a surrogate for phenotypic and genotypic
markers in correlation with development of
molecularly targeted therapies. As CTCs play a crucial
role in tumor dissemination, translational research is
implicating CTCs in several biological processes,
including epithelial to mesenchymal transition. In this
mini-review, we review CTCs in metastatic breast
cancer, and discuss their clinical utility for assessing
prognosis and monitoring response to therapy. We
will also introduce their utility in pharmacodynamic
monitoring for rational selection of molecularly
targeted therapies and briefly address how they can
help elucidate the biology of cancer metastasis.
Background
Affecting approximately 200,000 women in the United
States alone, breast cancer is now recognized to be a
heterogeneous disease comprised of several common
different phenotypes [1]. Due to increased screening,
awareness and consequent early detection, only approxi-
mately 5% of all breast cancer patients are initially diag-
nosed with incurable disease [2]. However, despite
optimal local and systemic adjuvant treatment, 30-40%
of patients diagnosed with curable breast cancer even-
tually die of recurrent disease [3,4]. Therefore, improved
techniques to both detect and treat metastatic breast
cancer are needed.
As early as the 1800’s when Recaimer first coined the
term “metastasis”, circulating tumor cells (CTCs) have
been postulated to be critical to the process [5,6]. The
development of disseminated disease has been tradition-
ally viewed as a sequential rather than concurrent pro-
cess, i.e.- the disease initially occurs at the primary site,
followed by local growth with eventual dissemination to
distant sites. However, emerging data is challenging this
theory [7,8]. In fact, the initiation of metastasis may be
a relatively early event in tumor biology, underscoring
the need to understand the significance of CTCs.
CTCs are now generally defined as nucleated cells
lacking CD45 and expressing cytokeratin [9,10]. Specifi-
cally, an antibody to the surface epithelial cell adhesion
molecule (epCAM) identifies cells of epithelial origin
circulating within the blood. Additionally, cytokeratin
antibodies further distinguish CTCs as those that are
not white blood cells (i.e. - CD45 negative) and select
for carcinomas (i.e. - anti-CK8, anti-CK18, anti-CK19).
Although multiple commercially available methods for
isolating CTCs exist [11,12], the CellSearch™ system
(Veridex Corporation, Warren, NJ) is the only FDA
approved system for clinical use with reproducible
results across many different laboratories. The Cell-
Search™ system has been fully described elsewhere [13];
but in summary, the system uses serum enriched for
nucleated cells expressing epithelial-cell adhesion mole-
cules, and fluorescently labels them for eventual detec-
tion by semi-automated fluorescence-based microscopy.
(Figure 1) In this minireview the clinical trials reviewed
all used the CellSearch™ system for CTCs isolation and
reporting. This minireview will focus exclusively on the
clinical utility of CTCs as it relates to patient care. We
will first review the clinical trial data that validated
CTCs ability to predict disease free and overall survival.
Additionally, more recent data comparing CTCs to
both standard imaging for metastatic breast cancer and
the newer [18F]fluorodeoxyglucose (FDG) positron
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will be reviewed as well as new data correlating CTC
burden as a surrogate for disease burden with the risk
of developing thromboembolic disease.
Clinical Utility
Predictive and Prognostic Capability
The first large, multi-institution, double-blind, prospec-
tive clinical trial evaluated the prognostic capability of
CTCs in patients with metastatic breast cancer (MBC)
[14]. One hundred and seventy-seven patients with mea-
surable disease had CTCs tested prior to beginning a
new palliative treatment regimen for progressive disease,
followed by repeat assessment at first follow-up visit
approximately 4 weeks later. This landmark trial pro-
spectively identified a CTC cut-off level of ≥5 cells per
7.5 ml of blood to be a reliable identifier of patients at
higher risk for disease progression and decreased
A
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Figure 1 (a) Schematic of Cell Tracks CTC separation system and (b) Detection of CTC. a. Epithelial cells are isolated from peripheral blood
using antibodies to Ep-CAM conjugated to magnetic particles. Cells are then analyzed to determine the number of CTC. b. Detection of CTC.
Two intact CTC are shown in the left panel, 33 damaged CTC in the central panel, and 6 cellular fragments in the right panel.
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tology, hormone receptor and HER2/neu status, or
whether the patient had recurrent or de novo metastatic
disease, those with <5 CTCs at baseline, and more
importantly, at first follow-up after beginning a new
treatment regimen, had superior progression free (PFS)
and overall survival (OS) (7 vs 2.1 months [p < 0.001]
and 10.1 vs >18 months, [p < 0.001], respectively). Addi-
tional CTCs assessment in this same patient cohort at
essentially monthly intervals following first follow-up
also confirmed improved PFS and OS for patients with
<5 CTCs at any subsequent time point. PFS and OS for
patients with <5 CTCs ranged from 5.6 to 7 months
and 18.6 to >25.0 months, respectively, compared to
those with ≥5 CTCs of 1.3 to 3.6 months PFS and 6.3 to
10.9 months OS (p = 0.001) [15].
Subsequent analysis of the eighty-three newly diag-
nosed patients undergoing first-line treatment for MBC
in the above study confirmed the ability of CTCs to pre-
dict response to therapy and global outcome. At first
follow-up assessment, median PFS for patients with <5
CTCs was 9.5 months, vs 2.1 months for those with ≥5
CTCs (p = 0.0057). Similarly, those with <5 CTCs had a
median OS of 18 months, compared to just 11 months
for those with ≥5 CTCs [16].
A similar analysis of the prognostic value of CTCs
among newly diagnosed MBC patients prior to begin-
ning first-line salvage therapy was performed in a large,
retrospective single-institution study [17]. This study
analyzed CTCs of 185 newly diagnosed MBC patients
diagnosed between 2001 and 2007. As previously seen,
patients with ≥5 CTCs at baseline had a greater than
three-and-a-half fold increased risk of death, (HR = 3.64
[95% CI, 2.11-6.30, p < 0.0001]) compared to those
patients with < 5 CTCs. The prognostic significance of
CTCs was independent of choice of therapy (i.e. - che-
motherapy with anthracyclines, taxanes, or both anthra-
cyclines/taxanes, hormone therapy), and was also
independent of hormone receptor status and HER-2/neu
status. Interestingly, in this cohort, although the patient
demographics were representative of the phenotypic
characteristics of MBC patients in general, i.e. - approxi-
mately two-thirds of patients hormone receptor positive
and approximately 20% HER-2/neu positive, greater
than half of the patients had bone as their first site of
metastatic disease. Upon multivariate analysis, patients
with bone metastasis, compared to other sites of disease
with ≥5 CTCs had an additional risk of death. (HR =
1.61; 95% CI 0.52-5.04 [p = 0.410]).
Additional analysis of CTCs and histologic breast can-
cer classification and phenotypes in a cohort of 517
MBC patients with either measurable or evaluable dis-
ease prior to commencement of new palliative treatment
regimens has yielded interesting observations and
hypothesis-generating information. Lobular histology
and bony (but not visceral) disease burden were asso-
ciated with higher numbers of CTCs [18]. In this study,
a closer evaluation of the chemo-naïve HER-2/neu MBC
patients treated with targeted HER-2/neu therapies,
showed that almost all (13 of 14) demonstrated a
decline in CTCs to <5, including patients with docu-
mented clinical and radiologic disease progression. At
time of the report, the median OS in these 13 patients
with CTCs decline had still not been reached, indicating
that CTCs of less than five, as previously shown, corre-
lated closely with superior prognosis, despite interval,
episodic progression.
A summary of clinical trials reviewed that served to
validate the predictive and prognostic capability of
CTCs can be seen in Table 1.
CTCs and Imaging
In the prospective, longitudinal, multi-institutional trial
described above, that demonstrated the ability of CTCs
to predict PFS and OS, a nested retrospective study of
138 of the 177 enrolled patients was performed with the
goal of comparing the predictive ability of CTCs assess-
ment to standard imaging [19]. While there was no cor-
relation between radiologic tumor burden and overall
CTC levels, radiographic response was concordant with
the established CTC cut-offs. Specifically, the almost
two-thirds of patients who had evidence of radiographic
response also had <5 CTCs at assessment, and an addi-
tional 16% had PD by both radiographic and CTCs (≥5)
criteria. However, CTC responders, whether radio-
graphic responders or non-responders, had similar sig-
nificantly improved median OS. CTC non-responders,
whether radiographic responders or not had worse out-
come. Additionally, greater intrareader and interreader
variability of interpretation of radiographic results com-
pared to CTC enumeration was found (15.2% vs 0.7%).
A separate retrospective study comparing the predictive
capability of [18F]fluorodeoxyglucose (FDG) positron
emission tomography (PET)/computed tomography
(CT) imaging to CTCs enumeration in a cohort of 115
patients with MBC, again demonstrated CTCs superior-
ity. As FDG-PET/CT is considered to be a promising
new imaging modality in assessment of response for
MBC patients [20-23], this radiographic assessment was
performed at the same intervals as CTCs assessment,
approximately 3 months after commencement of a new
treatment regimen for progression of disease. In 102
evaluable patients, CTCs response correlated with FDG-
PET/CT response 67% of the time, and in multivariate
analysis was the most significant predictor of OS (p =
0.04)[24]. CTCs response, therefore, is most likely an
accurate surrogate for radiographic response as well as
those with stable disease and this is reflected in the
superior clinical outcome associated with low number of
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during the course of palliative treatment signals impend-
ing treatment resistance and progression of disease.
Of note, while CTC level does not correlate with
radiographic measurable disease burden, CTC burden
does correlate with extent ofb o n yd i s e a s ei n v o l v e m e n t .
Relative to those without bone involvement, patients
with multiple sites of disease including bony disease
with ≥5 CTC had significantly worse outcome (p =
0.0008). This is in contrast to patients with minimal or
no bone involvement, suggesting a potential biologic
link between bone metastases and CTCs [25].
CTCs and Thromboembolic Disease
In a single institution, retrospective review, Mego and
colleagues assessed CTCs level in 290 MBC patients
prior to starting a new palliative treatment regimen. The
presence of ≥1 CTCs, - the cut-off commonly employed
in the adjuvant setting [14,26], was associated with a
four-fold increase in thrombosis compared to patients
who had no CTCs [27]. Although not statistically signifi-
cant, patients with ≥5 CTCs were almost twice as likely
to experience a thrombotic event (6.6 vs 11.6%, p =
0.076). When lines of therapy and extent of tumor
burden were controlled for by multi-variate analysis, evi-
dence of at least one CTC was still associated with
greater than five-fold increase in the risk of thrombosis
compared with those without any detectable CTC, thus
confirming that CTCs, while not directly correlated with
volume of disease burden, are a marker of increased
morbidity that ultimately impacts mortality.
This observation indicates a potential role of clotting
factors in the peripheral blood in some steps of the
metastatic process. In fact, the environment in the
bloodstream is highly unfavorable to tumor cells due to
physical forces, presence of immune cells and death
upon detachment (anoikis), which contributes to meta-
static insufficiency [28]. Coagulation factors play an
important role in metastasis and enhance breast cancer
progression in animal models [29,30]. The binding of
tumor cells to coagulation factors, including tissue fac-
tor, fibrinogen, fibrin and thrombin, creates an embolus
and facilitates arrest in capillary beds followed by the
establishment of metastasis [31]. This concept is further
supported by a meta-analysis that showed anticoagula-
tion therapy has beneficial effects on cancer patient sur-
vival [32]. However, the anti-metastatic effect of heparin
Table 1 Summary of clinical trials reviewed that served to validate the predictive and prognostic capability of CTCs
Study Design Primary
Objective
Prospective
orRetrospective
N Line of
therapy
Median PFS (months) Median OS (months)
1. Multi-institution, double-blind, clinical trial of
patients with MBC with measurable disease
beginning a new therapy. CTCs assessed at
baseline and at 1
st follow-up clinical visit,
approximately 3-4 weeks after starting
therapy.
14
PFS, OS Prospective 177 Any 7.0 vs 2.7; p < 0.001
baseline assessment 7.0
vs 2.1; p < 0.001 1
st
follow-up
>18 vs 10.1; p < 0.001
baseline assessment >18
vs 8.2; p < 0.001 1
st
follow-up
2. Multi-institution, double-blind, clinical trial of
patients with MBC with measurable disease on
treatment. CTCs assessed at 2
nd follow-up and
subsequent follow-up clinical visits up to 9
months of follow-up. Sub-study of #1 above.
15
PFS, OS Prospective 177 Any 5.6 - 7 vs 1.3 - 6; p = n/
a
18.6- >25 vs 6.3 - 10.9; p
= 0.001
3. Multi-institution, double-blind, clinical trial of
patients with MBC with measurable disease
beginning a new therapy. CTCs assessed at
baseline and 1
st follow-up clinical visit,
approximately 3-4 weeks after starting therapy
for the 47% of patients who were being
treated with 1
st line palliative therapy. Sub-
study of #1 above.
16
PFS, OS Prospective 83 1
st line 9.5 vs 4.9, p = 0.0014
baseline assessment 9.5
vs 2.1, p = 0.0057 1
st
follow-up
>18 vs 14.2, p = 0.0048
baseline assessment >18
vs 11.1, p = 0.0012 1
st
follow-up
4. Single institution, retrospective analysis of a
cohort of newly diagnosed MBC patients
(either with de novo MBC or newly diagnosed
recurrent MBC) who had CTCs assessed at the
time of initial diagnosis of MBC between 2001
and 2007. CTCs assessed at baseline, prior to
starting salvage therapy.
17
OS Retrospective 185 1
st line 28.3 vs 15, p < 0.001
5. Single institution assessment of a cohort of
MBC patients prior to starting a new treatment
regimen. CTCs assessment correlated with
histology and phenotypic subtypes of breast
cancer.
18
Exploratory
OS
Retrospective 517 Any
CTC cut-off used in all of these clinical trials compared those patients with less than 5 CTCs (<5 CTCs), compared to those who had 5 or greater CTCs (≥5 CTCs)
per 7.5 ml of whole blood.
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ability to inhibit the interactions between some oligosac-
charides present on tumor cells and P-selectin on plate-
lets [33,34].
Summary and Future Directions
Elevated CTCs, whether at baseline or at any time
throughout the course of MBC are an ominous prognos-
tic indicator. Whether by standard imaging studies and/
or PET/CT imaging, elevated CTCs while on treatment,
regardless of radiographic assessment, ultimately are
predictive of an ineffective therapy. Similarly, low CTCs,
especially while on treatment, predict for favorable
survival as well as response to therapy. CTCs also reflect
tumor biology as well as aspects of the host microenvir-
onment as patients with elevated CTCs have an
increased risk of developing thromboembolic disease.
Taken as a whole, CTCs, while not directly correlated
with volume of disease burden, are a marker of
increased morbidity that ultimately impacts mortality.
Despite major advances in our understanding of can-
cer biology, we still lack detailed insight into the
mechanisms of tumor establishment and dissemination.
CTCs play a crucial role in tumor dissemination in rela-
tion to several biological processes, including epithelial
to mesenchymal transition (EMT,) the process whereby
Figure 2 Schematic of SWOG SO500. A randomized phase III trial to test the strategy of changing therapy vs maintaining therapy for
Metastatic Breast Cancer patients who have elevated circulating tumor cell levels at first follow-up assessment.
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down-regulation of epithelial associated E-cadherin, and
up-regulation of mesenchymal N-cadherin, allowing
them to invade the extracellular matrix and migrate to a
distant site [7]. The c-DNA of various genes such as
Twist1, Akt2 and PI3Ka, associated with EMT and the
stem cell marker, ALDH1, can be detected in CTCs. In
patients with MBC not responding to the prescribed
therapeutic regimen, the identification of EMT markers
in the CTCs was considerably higher than in normal
healthy individuals without a cancer diagnosis as well as
patients with MBC who were responding to therapy
[35].
HER-2 amplification by fluorescent in situ hybridiza-
tion (FISH) has been detected in CTCs, both concordant
and discordant with the primary tumor phenotypic ana-
lysis. Interestingly, trastuzumab based therapy was admi-
nistered to 4 of 9 patients with MBC in whom HER-2
positive CTC cells were detected, despite the primary
site testing HER-2 negative by standard pathology tech-
niques. Three of those four patients responded - one
experiencing a complete response and two experiencing
partial responses. This modest sample validates the
hypothesis that the most relevant tumor cell population
is the one that has proven ability to disseminate through
the blood stream and may be the most representative
population of metastatic disease [35]. Additionally, the
possibility of collecting sequential blood samples for
r e a l - t i m em o n i t o r i n go ft h ee f f i c a c yo fs y s t e m i ct h e r a -
pies offers new possibilities to evaluate targeted thera-
pies based on genomic profiling of CTCs and to
improve the clinical management of patients with
advanced disease [35-37]. This strategy is currently
undergoing its first, large prospective, randomized vali-
dation study [38]. Patients who enroll on this study and
have elevated CTCs will be randomized to either main-
tain therapy or switch treatments prior to standard re-
staging by radiographic assessment (Figure 2).
Conclusion
In conclusion, CTC assessment has been shown to be a
repeatedly, strong and reliable predictor of outcome in
metastatic breast cancer. It pe r f o r m sa sr e l i a b l ya si m a -
ging studies for assessment of response to therapy, and
possibly more so. Although the mechanism is not fully
elucidated, CTCs are a unique and heterogeneous cell
population with established prognostic and predictive
value in MBC particularly in defined subtypes of breast
disease, and may related to bone biology in particular.
In the era of biologically targeted therapies, molecular
characterization of CTCs may hold the key to future
pharmacodynamic assessment in drug development of
MBC. Currently, most molecularly targeted biologic
therapies are developed using the same toxicity
assessment as traditional cytotoxic therapies - identify-
ing the maximum tolerated dose. However, in the case
of these newer molecularly targeted therapies, the maxi-
mum tolerated dose may not necessarily correlate with
the most effective dose - i.e. receptor downregulation,
protein phosphorylation, etc. The ability to repeatedly
sample an accessible tumor population such as CTCs
may allow selection of optimal therapies based on con-
firmed target delivery. Considerable effort is currently
being directed at developing additional technologies to
be able to reliably characterize the genomic and proteo-
mic information contained within these cells. The full
extent of CTCs utility has yet to be explored.
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